🌾 Post-Treatment Lyme Disease Syndrome (PTLDS) Simulator

Completed Antibiotic Course

Patient finishes the recommended antibiotic regimen for Lyme disease.

• 14–21 d: Typical course (Doxycycline standard)
• Oral: Route (IV for late disease)
• High: Adherence (Placeholder metric)
• Scheduled: Follow-up (Post-tx check)

Placeholder section heading

Short placeholder text about completing treatment.

Spirochete Clearance Confirmed

Serologic and clinical markers indicate the infection is resolved.

• Clinical: Clearance marker (No direct test of cure)
• Persists: Serology (Antibodies remain positive)
• Low: Reinfection risk (Placeholder value)
• ~1 mo: Timeframe (Post-treatment)

Placeholder section heading

Short placeholder text about clearance confirmation.

Persistent Fatigue and Arthralgia

Some patients report ongoing fatigue and joint pain despite cure.

• ~10-20%: PTLDS fatigue (Placeholder estimate)
• Common: Arthralgia (Placeholder descriptor)
• >6 mo: Duration (Defines PTLDS)
• Variable: Severity (Placeholder value)

Placeholder section heading

Short placeholder text about fatigue and arthralgia.

Cognitive Impairment Symptoms

Brain fog, memory, and concentration complaints may persist.

• Reported: Brain fog (Placeholder descriptor)
• Mild deficit: Memory (Placeholder estimate)
• Reduced: Concentration (Placeholder value)
• Functional: Impact (Placeholder descriptor)

Placeholder section heading

Short placeholder text about cognitive symptoms.

PTLDS Risk Factor Assessment

Delayed diagnosis and disseminated stage raise PTLDS likelihood.

• Key factor: Delayed dx (Placeholder descriptor)
• Key factor: Disseminated stage (Placeholder descriptor)
• Protective: Early treatment (Placeholder descriptor)
• Computed: Risk gauge (From sliders)

Placeholder section heading

Short placeholder text about risk factors.

Placeholder highlight: earlier treatment lowers PTLDS risk.